Abstract. This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that. Risk of febrile neutropenia (FN) should be systematically assessed (in consultation with infectious disease specialists as needed), including. Febrile neutropenia (FN) is a serious complication of cancer chemotherapy that The Infectious Diseases Society of America (IDSA), National.
|Published (Last):||15 October 2006|
|PDF File Size:||6.5 Mb|
|ePub File Size:||18.54 Mb|
|Price:||Free* [*Free Regsitration Required]|
If they have initiated IV antibiotics, patients who meet criteria for being at low risk Table 3 and can tolerate oral medications may be candidates for transitioning to combination oral antibiotics. In the absence of significant impairment of gastrointestinal function idza, nausea, vomiting, diarrhea, malabsorption, and poor oral intakean oral antibiotic regimen may be undertaken to complete the full course of therapy.
Studies have demonstrated inconsistent results regarding the use of such markers neurropenia inflammation as C-reactive protein, interleukins-6 and -8, and procalcitonin in neutropenic patients with cancer [ 55—57 ].
Fever and Neutropenia in Adults with Cancer
Selected hospitalized patients who meet criteria for being at low risk may be transitioned to the outpatient setting to receive either IV or oral antibiotics, as long as adequate daily follow-up is ensured B-III. Cefepime versus imipenem-cilastatin as empirical monotherapy in febrile patients with short duration neutropenia.
In recent years, an increasing incidence and array of antibiotic-resistant pathogens have become significant challenges in the treatment of neutroppenia and other hospitalized patients [ 5—71113—1461—62 ]. Patients meeting select criteria of clinical stability and adequate gastrointestinal absorption may be eligible for treatment switch from intravenous to oral administration of antibiotics.
Previous fungal infection means demonstrated fungal infection or empirically treated suspected fungal infection. Patients with FN with high risk of complications should be initiated with empiric antibiotics administered intravenously in the hospital setting.
The specimen can be tested by PCR, direct antigen assay, or culture for respiratory viruses including influenza, parainfluenza, adenovirus, RSV, and human metapneumovirus [ ]. The majority of patients who develop fever during neutropenia have no identifiable site of infection and no positive culture results.
Persistent fever in an otherwise asymptomatic and hemodynamically stable patient is not a reason for undirected antibiotic additions or changes. However, neutropenia is not a predisposition to reactivation of either virus; thus, prevention strategies for these febile herpes viruses are not discussed in this document [ ].
Examination and culture of spinal fluid is indicated if meningitis is suspected.
Prophylaxis with micafungin or caspofungin is efficacious and well-tolerated for the prevention of candidiasis and invasive aspergillosis in high-risk patients . All members of the Panel complied with the IDSA policy on conflicts of interest, which requires disclosure of any financial or other interest that might be construed as constituting an actual, febrilf, or apparent conflict. Risk assessment in cancer patients with fever and neutropenia: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States.
Specific definitions of high and low risk are given below. Notably, monotherapy regimens, including cefepime, carbapenems and piperacillin-tazobactam, provide excellent coverage of viridans streptococci and are considered to be adequate solo agents for the treatment of febrile neutropenia in patients with oral mucositis, precluding the need for the addition of vancomycin to the regimen [ ].
Guidelines in the Management of Febrile Neutropenia for Clinical Practice
Bacteremia due to viridans group Streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Deep-tissue candidiasis, such as hepatic or hepatosplenic disease, esophagitis, or endocarditis, is much less common. Although these options are used in some centers, there are currently no published trials to confirm their efficacy and safety. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Nonetheless, concerns about neutropeniz cefepime use prompted the US Food and Drug Administration FDA to undertake a second comprehensive meta-analysis, using an expanded dataset of all cefepime-based studies involving fever and neutropenia including many not included in the earlier meta-analysis .
IDSA GUIDELINES Bundle (free trial) – Fever and Neutropenia
Patients receiving fluoroquinolone prophylaxis should not receive oral empirical therapy with a fluoroquinolone A-III. There is less evidence to support routine additions of vancomycin or an antifungal agent to antimicrobial regimens [ ].
Switching from febrlle inpatient antibiotic regimen to outpatient oral or IV regimens for patients who have defervesced, combined with careful daily follow up, may also be a reasonable alternative to prolonged hospitalization of patients waiting for bone marrow recovery.
All patients at high risk by MASCC or by clinical criteria should be initially admitted to the hospital for empirical antibiotic therapy if they are not already inpatients B-I.
Modifications for specific documented infections are discussed below, with the caveat that local patterns of susceptibility are the most critical factor in making final decisions.
Trends and antimicrobial resistance of pathogens causing bloodstream infections neitropenia febrile neutropenic adults with hematological malignancy.
Sputum samples for routine bacterial culture should be sent if the patient has a productive cough.
IDSA GUIDELINES Bundle (free trial)
An air-crescent sign is insensitive and generally appears late, if at all [ ]. As with vancomycin, newer gram-positive agents, such as linezolid, quinupristin-dalfopristin, tigecycline, televancin, or daptomycin, have no proven role in routine empirical coverage. However, fluconazole lacks anti-mold febrilf its prophylactic efficacy in the HSCT population can be attributed to prevention of invasive candidiasis [ ]. Identification of a clinically or microbiologically documented infection should guide any changes to the initial empirical antibiotic regimen.
The searches were limited to human-only studies and to specific study design or publication type: Hospital work exclusion policies should be designed to encourage health care workers HCWs to report their illnesses or exposures A-II. However, netropenia agents may be considered in modifications of initial treatment as additional therapy for patient-based needs, such as suspicion of catheter-related infection, skin or soft-tissue infection, pneumonia, hemostatic instability, or antibiotic resistance.
Febrilr more information, please visit the ASCO website. Patients with respiratory signs and symptoms should have a chest radiograph to rule out pneumonia.